S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33

ObsEva Stock Forecast, Price & News

-0.01 (-0.32 %)
(As of 09/24/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume565,260 shs
Average Volume2.98 million shs
Market Capitalization$181.29 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive OBSV News and Ratings via Email

Sign-up to receive the latest news and ratings for ObsEva and its competitors with MarketBeat's FREE daily newsletter.

ObsEva logo

About ObsEva

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for woman's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.63 out of 5 stars

Medical Sector

965th out of 1,352 stocks

Pharmaceutical Preparations Industry

475th out of 666 stocks

Analyst Opinion: 3.3Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

ObsEva (NASDAQ:OBSV) Frequently Asked Questions

Is ObsEva a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ObsEva in the last year. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ObsEva stock.
View analyst ratings for ObsEva
or view top-rated stocks.

What stocks does MarketBeat like better than ObsEva?

Wall Street analysts have given ObsEva a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ObsEva wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting ObsEva?

ObsEva saw a drop in short interest during the month of August. As of August 13th, there was short interest totaling 1,490,000 shares, a drop of 35.8% from the July 29th total of 2,320,000 shares. Based on an average daily volume of 1,770,000 shares, the days-to-cover ratio is currently 0.8 days. Approximately 2.5% of the shares of the stock are short sold.
View ObsEva's Short Interest

When is ObsEva's next earnings date?

ObsEva is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for ObsEva

How were ObsEva's earnings last quarter?

ObsEva SA (NASDAQ:OBSV) released its earnings results on Thursday, August, 5th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.01.
View ObsEva's earnings history

How has ObsEva's stock been impacted by COVID-19?

ObsEva's stock was trading at $2.57 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, OBSV stock has increased by 22.6% and is now trading at $3.15.
View which stocks have been most impacted by COVID-19

What price target have analysts set for OBSV?

4 brokerages have issued 12 month price targets for ObsEva's stock. Their forecasts range from $5.00 to $21.00. On average, they expect ObsEva's share price to reach $14.33 in the next twelve months. This suggests a possible upside of 355.0% from the stock's current price.
View analysts' price targets for ObsEva
or view top-rated stocks among Wall Street analysts.

Who are ObsEva's key executives?

ObsEva's management team includes the following people:
  • Brian O'Callaghan, Chief Executive Officer & Director
  • David Renas, Chief Financial Officer
  • Jean-Pierre Gotteland, Chief Scientific Officer, Head-R&D
  • Elizabeth Ijeoma Onyemelukwe Garner, Chief Medical Officer
  • Elke Bestel, VP, Head-Drug Safety & Pharmacovigilance

What other stocks do shareholders of ObsEva own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ObsEva investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Trevena (TRVN), Zosano Pharma (ZSAN), Vaxart (VXRT), VBI Vaccines (VBIV), Bionano Genomics (BNGO) and ADMA Biologics (ADMA).

When did ObsEva IPO?

(OBSV) raised $98 million in an IPO on Thursday, January 26th 2017. The company issued 6,500,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.

What is ObsEva's stock symbol?

ObsEva trades on the NASDAQ under the ticker symbol "OBSV."

Who are ObsEva's major shareholders?

ObsEva's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Morgan Stanley (1.50%), Morgan Stanley (1.50%), Credit Suisse AG (1.47%), Zurcher Kantonalbank Zurich Cantonalbank (0.95%), Susquehanna International Group LLP (0.00%) and Deutsche Bank AG (0.34%).

Which major investors are selling ObsEva stock?

OBSV stock was sold by a variety of institutional investors in the last quarter, including Zurcher Kantonalbank Zurich Cantonalbank, Marshall Wace LLP, Marshall Wace LLP, and Banque Cantonale Vaudoise.

Which major investors are buying ObsEva stock?

OBSV stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Deutsche Bank AG, Simplex Trading LLC, Jump Financial LLC, Susquehanna International Group LLP, Renaissance Technologies LLC, and Group One Trading L.P..

How do I buy shares of ObsEva?

Shares of OBSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ObsEva's stock price today?

One share of OBSV stock can currently be purchased for approximately $3.15.

How much money does ObsEva make?

ObsEva has a market capitalization of $181.29 million and generates $20,000.00 in revenue each year. The company earns $-82,970,000.00 in net income (profit) each year or ($1.67) on an earnings per share basis.

How many employees does ObsEva have?

ObsEva employs 45 workers across the globe.

What is ObsEva's official website?

The official website for ObsEva is www.obseva.com.

Where are ObsEva's headquarters?

How can I contact ObsEva?

ObsEva's mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The company can be reached via phone at (122) 552-3840 or via email at [email protected].

This page was last updated on 9/26/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.